InnoHK Hong Kong Center for Neurodegenerative Diseases (InnoHK HKCeND) participated in LEAP East 2026 from 8 to 10 Jul 2026 at the Hong Kong Convention and Exhibition Centre, showcasing its latest research innovations and engaging with stakeholders at the Hong Kong Pavilion, set up by the Innovation, Technology and Industry Bureau (ITIB).
LEAP East 2026 marked the first LEAP conference held outside Saudi Arabia and the inaugural LEAP East hosted in Hong Kong. The three-day event brought together industry leaders, investors, technology entrepreneurs, and researchers across the Asia-Pacific and Middle East, featuring technology fields including artificial intelligence (AI), deep tech, smart cities, and new energy. The conference attracted more than 35,000 participants, including 340 speakers, 450 exhibitors, and over 400 investors from 30 countries and regions.
At the Pavilion, InnoHK HKCeND highlighted key R&D achievements, particularly its latest advance in a blood assay for brain-derived pTau217. pTau217 is one of the most promising blood biomarkers and is widely recognized as a valuable tool for detecting Alzheimer’s disease pathology. Compared with assays measuring total pTau217, this blood assay enhances accuracy in detecting and staging Alzheimer’s disease-related brain pathology, laying an important foundation for the development of a high-performance diagnostic tool in clinical settings. The technology has been licensed to Cognitact Limited, and related blood test services have been adopted by multiple hospitals and clinics, assisting diagnosis and treatment.
Throughout the event, the team exchanged insights with stakeholders and explored cross-industry and cross-border collaboration opportunities, helping to accelerate the translation of scientific discoveries into real-world impact and supporting Hong Kong’s development as an international I&T hub.
